85/100 · Critical
Manufactured by Janssen Pharmaceuticals, Inc.
Risperidone shows significant safety concerns, particularly with hormonal and weight-related side effects.
254,329 FDA adverse event reports analyzed
Risperidone has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 254,329 adverse event reports for this medication, which is primarily manufactured by Janssen Pharmaceuticals, Inc..
The most commonly reported adverse events include Gynaecomastia, Off Label Use, Abnormal Weight Gain. Of classified reports, 66.3% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Gynecomastia and hyperprolactinemia are prominent adverse events, indicating potential hormonal disruption.
Weight gain and increased weight are frequently reported, suggesting a significant metabolic impact. A notable proportion of reports involve 'off-label use' or 'product use in unapproved indication', raising concerns about appropriate prescribing. Serious outcomes, including suicide attempts and death, are reported at a concerning rate (66.3% of total outcomes).
Patients taking Risperidone should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Risperidone may interact with other medications, potentially altering its effectiveness or increasing side effect risk. Caution is advised when combining with drugs affecting dopamine or serotonin pathways. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Risperidone received a safety concern score of 85/100 (high concern). This is based on a 66.3% serious event ratio across 129,886 classified reports. The score accounts for 254,329 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Male: 74,270, Female: 41,455, Unknown: 541. The most frequently reported age groups are age 17 (1,304 reports), age 15 (1,258 reports), age 16 (1,220 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Risperidone may interact with other medications, potentially altering its effectiveness or increasing side effect risk. Caution is advised when combining with drugs affecting dopamine or serotonin pathways.
If you are taking Risperidone, here are important things to know. The most commonly reported side effects include gynaecomastia, off label use, abnormal weight gain, weight increased, drug ineffective. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Discuss any concerns about weight changes or hormonal symptoms (e.g., breast enlargement) with your doctor immediately. Ensure your doctor is aware of all other medications and supplements you are taking to avoid potential drug interactions. Report any new or worsening mental health symptoms, such as suicidal thoughts, to your healthcare provider promptly. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Risperidone is an antipsychotic medication with a known risk profile for metabolic and endocrine side effects, which are reflected in the reported adverse events.
The FDA has received approximately 254,329 adverse event reports associated with Risperidone. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Risperidone include Gynaecomastia, Off Label Use, Abnormal Weight Gain, Weight Increased, Drug Ineffective. By volume, the top reported reactions are: Gynaecomastia (24,608 reports), Off Label Use (12,324 reports), Abnormal Weight Gain (9,446 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Risperidone.
Out of 129,886 classified reports, 86,063 (66.3%) were classified as serious and 43,823 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Risperidone break down by patient sex as follows: Male: 74,270, Female: 41,455, Unknown: 541. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Risperidone adverse events are: age 17: 1,304 reports, age 15: 1,258 reports, age 16: 1,220 reports, age 52: 1,207 reports, age 14: 1,165 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Risperidone adverse event reports is Janssen Pharmaceuticals, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Risperidone include: Emotional Disorder, Product Use In Unapproved Indication, Injury, Drug Interaction, Hyperprolactinaemia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Risperidone to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Risperidone has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Gynecomastia and hyperprolactinemia are prominent adverse events, indicating potential hormonal disruption.
Key safety signals identified in Risperidone's adverse event data include: GYNAECOMASTIA. HYPERPROLACTINAEMIA. ABNORMAL WEIGHT GAIN. SUICIDE ATTEMPT. DRUG INTERACTION. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Risperidone may interact with other medications, potentially altering its effectiveness or increasing side effect risk. Caution is advised when combining with drugs affecting dopamine or serotonin pathways. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Risperidone.
Discuss any concerns about weight changes or hormonal symptoms (e.g., breast enlargement) with your doctor immediately. Ensure your doctor is aware of all other medications and supplements you are taking to avoid potential drug interactions. Report any new or worsening mental health symptoms, such as suicidal thoughts, to your healthcare provider promptly.
Risperidone has 254,329 adverse event reports on file with the FDA. Weight gain and increased weight are frequently reported, suggesting a significant metabolic impact. The volume of reports for Risperidone reflects both the drug's usage level and the vigilance of the reporting community.
Risperidone is an antipsychotic medication with a known risk profile for metabolic and endocrine side effects, which are reflected in the reported adverse events. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.